FMC CORP Q3 FY2026 earnings call

• Commercial Actions & Inventory Reset: FMC announced significant commercial actions on October 15 to address channel inventory constraints caused by customers holding high-value stock from previous higher-price models. This resulted in a $672 million EBITDA charge.
• North America Business Model Transition: Transitioning the North American model to lower upfront prices with reduced rebates to align customer inventory value with market conditions. Approximately $500 million of the charge relates to this transition and adjusting historic inventory values.
• International Price Adjustments: Reducing prices for select high-priced products in Brazil, Argentina, US, and Canada to facilitate downstream movement. This accounts for ~$175 million of the charge and is expected to reduce future cash collections.
• Underlying Performance Issues: Q3 underlying sales missed guidance due to lower volumes and price headwinds from strategic pricing actions on expired IP products. Customer replenishment orders dropped sharply in late September.
• Strategic Priorities: Focus is shifting from cost-cutting (SG&A flat, absorbing inflation) to top-line growth via new active ingredients (Fluent Appear, Isoflex, Dudilex) and improved channel flow. R&D spending is maintained at current levels.
• Divestitures & Liquidity: Sale of India business targeted for December 1 close; Delaware site sale-leaseback expected by year-end. Tessenderlo Group invested $403 million for ~20% stake. Net debt ended Q3 at ~$3.4 billion.

The transcript does not provide a breakdown of financial performance by specific product segment (e.g., Crop Protection, Seed Treatment) in terms of absolute revenue contribution percentages. The company reports consolidated figures: Total Revenue was $106 million (including $639 million commercial action impact); underlying sales excluding India and commercial actions were $745 million. Adjusted EBITDA was negative $559 million (including $672 million charge); underlying adjusted EBITDA was $113 million.

• Q4 2026 Revenue: Expected between $1.04 billion and $1.14 billion (midpoint flat vs prior year). Driven by high-single-digit price declines offset by volume growth from direct-to-grower sales in Brazil and new products.
• Q4 2026 Adjusted EBITDA: Expected between $210 million and $230 million (down 22% YoY). Lower pricing and FX headwinds partially offset by higher volumes and favorable costs.
• Q4 2026 Adjusted EPS: Expected between $0.56 and $0.70.
• Full Year 2026 Free Cash Flow: Revised downward to negative $350 million to negative $150 million. Driven by lower Q3/Q4 EBITDA, lower collections, and $180 million in restructuring spending. Free cash flow before restructuring is expected to be negative $170 million to positive $30 million.
• 2027 Preliminary Outlook: Sales expected to mark a financial inflection point. Adjusted EBITDA guided to at least $650 million up to $730 million. Growth driven by new actives, lower returns/rework, and partial manufacturing cost benefits.
• 2028 Preliminary Outlook: Adjusted EBITDA expected between $760 million and $840 million. Stronger growth from fully commercialized new actives and full-year manufacturing footprint benefits.

• Channel Inventory Constraints: High inventory values held by customers are delaying product movement and constraining replenishment orders.
• Demand Uncertainty: Weak demand in key markets, exacerbated by potential El Niño impacts on grower margins.
• Price Volatility: Significant price declines in Q4 2026 due to post-patent competitive pressures.
• Cash Flow Pressure: Negative free cash flow outlook for 2026 due to working capital issues, lower collections, and restructuring costs.
• Execution Risk: Success depends on timely implementation of commercial actions and rapid absorption of new products into the market.
• FX Volatility: Modest FX headwinds at EBITDA level; Brazilian Real volatility following local elections.

Q: Analyst asked about 2027 free cash flow drivers and whether the $175M international price adjustment represents a permanent cash loss or receivable write-down.

A: CFO clarified that 2026 FCF assumes flat prepayments vs 2025. For 2027, EBITDA growth will drive FCF, though restructuring spending remains high ($180M in 2026, lower in 2027). The $175M adjustment will be executed via credit notes against future orders or AR reductions, creating a theoretical cash headwind over 4-6 quarters as it reduces future cash receipts, though accelerated collection of previously stagnant inventory may offset some losses.

Q: Analyst questioned SG&A cost structure efficiency given sales decline and asked if R&D spending would be cut.

A: CEO explained SG&A % increased solely due to sales decline, not absolute spend increases; SG&A has remained flat while absorbing inflation. Major cost cuts have already been implemented ($300M SG&A reduction, plant closures). Future focus is strictly on top-line growth through new actives and channel normalization. R&D spending will be maintained at current levels to support pipeline growth, though partnership models may be explored later.

Q: Analyst requested accounting details and split of the $500M North American charge, specifically the double-entry impact on P&L, BS, and CF.

A: CFO stated the $500M charge splits ~60/40 between the new pricing structure mechanics and adjusting historic inventory gross-to-net prices. Accounting entries primarily impacted accrued rebates, trade receivables, and advance payments. The charge is non-cash in Q3; cash impacts occur in future periods only for the $175M international component, not the $500M rebate restructuring, which is cash-neutral over the crop cycle.

Q: Analyst asked about the India divestiture working capital extraction and FX impact of Brazilian election volatility on guidance.

A: CFO confirmed the India transaction is on track for Dec 1 close with a fair value of $260M. ~$115M collected YTD; remaining proceeds expected at closing. Regarding FX, the Brazilian Real volatility post-election reversed earlier strengthening trends. Current planning incorporates these rates, and no specific additional headwind beyond standard hedging assumptions was added to the Q4 or 2027 outlook.